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A 47-year-old female was admitted to our hospital for treatment of end-stage liver disease due to primary biliary
cirrhosis. Preoperative routine nasal sinus magnetic resonance imaging revealed diffuse inflammatory mucosal
hyperplasia of the right maxillary sinus and mycetoma without invasive fungal sinusitis. Aspergillus antigen was
positive. With a diagnosis of sinus aspergillosis, endoscopic sinus drainage and removal of mycetoma were
performed. After endoscopic treatment, the right maxillary sinus was irrigated using amphotericin B for 2 weeks
and then treated by iodine with gentamicin and ketoconazole for 6 weeks. At 1 month after endoscopic treatment,
the mycetoma had disappeared. At 3 months after the endoscopic treatment, the patient underwent living-donor
liver transplantation using the left and caudate lobe of her daughter. The patient made a satisfactory recovery and
was discharged on 19 days after transplant. As of 44 months after transplant, she remains well without recurrence
of aspergillosis.
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In immunosuppressed patients including organ trans-
plant recipients, infection with Aspergillus species results
in excess mortality rates with the range from 58% to
87% [1,2]. Therefore, pre-transplant evaluation of infec-
tious complications and complete elimination of infectious
focuses are important. We report a liver transplant recipi-
ent after treatment of sinus aspergillosis by endoscopic
mycetoma removal and sinus drainage. To the best of our
knowledge, such a case has not been reported in the
English literature.Case presentation
A 47-year-old female was admitted to our hospital for
treatment of end-stage liver disease (ESLD) due to pri-
mary biliary cirrhosis (PBC). The patient had undergone
endoscopic treatment for ruptured esophageal varices in
2003 and had hypothyroidism and Sjögren’s syndrome.
The patient’s model for end-stage liver disease score was
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diffuse inflammatory mucosal hyperplasia of the right
maxillary sinus and mycetoma without invasive fungal
sinusitis (Figure 1A). Histological examination of myce-
toma revealed aspergillosis. Before treatment of the sinus
aspergillosis, laboratory investigations included C-reactive
protein of 2.0 mg/dl, beta-D glucan less than 4 pg/ml, and
positive Aspergillus antigen (Figure 2). With a diagnosis of
sinus aspergillosis, endoscopic sinus drainage and removal
of the mycetoma were performed. The pathological diag-
nosis was aspergillosis of the right maxillary sinus. After
endoscopic treatment, the right maxillary sinus was irri-
gated using amphotericin B for 2 weeks and then treated
with gentamicin and ketoconazole after flushing using
iodine for 6 weeks. At 1 month after endoscopic treat-
ment, diffuse inflammatory mucosal hyperplasia of the
right maxillary sinus improved and the mycetoma had
disappeared (Figure 1B), and Aspergillus had become
negative in maxillary culture. Before liver transplantation,
beta-D glucan was less than 4 pg/ml; however, Aspergillus
antigen remained positive, and C-reactive protein ranged
from 1.4 to 2.4 mg/dl (Figure 2). At 3 months after the
endoscopic treatment, the patient underwent living-donoropen access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Figure 1 Pre- and postoperative nasal sinus magnetic resonance images are shown. Preoperative routine nasal sinus magnetic resonance
image revealed diffuse inflammatory mucosal hyperplasia of the right maxillary sinus, and a mycetoma without invasive fungal sinusitis in
T2-weighted image ((A), arrow). At 1 month after endoscopic treatment, diffuse inflammatory mucosal hyperplasia of the right maxillary sinus
improved and mycetoma disappeared ((B), arrowhead).
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lobe of her daughter. Tacrolimus and steroids were used
for initial immuno-suppression. For postoperative antifun-
gal prophylaxis, micafungin was used for 10 days and,
thereafter, voriconazole for 7 weeks. The patient made a
satisfactory recovery and was discharged on 19 days after
LDLT. As of 44 months after transplant, she remains well
without recurrence of aspergillosis.
Conclusions
Advances in surgical technique, immunosuppressive agent,
and perioperative management have improved therapeutic
outcome of liver transplantation. Fungal infections are one
of the most important infectious complications of liverFigure 2 Before endoscopic treatment, C-reactive protein was 2.0 mg
treatment, the right maxillary sinus was irrigated using amphotericin B for
for 6 weeks. At 3 months after the endoscopic treatment, the patient unde
after transplantation.transplantation, contributing significantly to both morbid-
ity and mortality [3].
Incidence of Aspergillus infections has been reported in
1% to 15% of organ transplant recipient. In invasive asper-
gillosis, the reported mortality rate ranges from 74% to
92% [4]. Therefore, postoperative antifungal prophylaxis
and treatment are important to improve therapeutic out-
come of liver transplantation [5]. Because preoperative
presence of aspergillosis may be a high risk factor for
postoperative fatal aspergillosis, complete elimination of
infectious lesion before liver transplantation is necessary.
Endoscopic sinus surgery is the gold standard for treat-
ment of sinus aspergillosis with normal immune pa-
tients and antifungal therapy is unnecessary [6,7]. The/dl and beta-D glucan was less than 4 pg/ml. After endoscopic
2 weeks and then treated by iodine with gentamicin and ketoconazole
rwent living-donor liver transplantation and was discharged on 19 days
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gillosis is not established on the United States practice
guidelines for aspergillosis [8]. Therefore, during the
first 10 days after liver transplantation, micafungin was
used for antifungal prophylaxis due to less drug inter-
action with tacrolimus. Then, antifungal prophylaxis was
switching from micafungin to voriconazole, which is rec-
ommended for treatment of invasive aspergillosis on the
United States guideline. Tsuchiya et al. reported a case of
successful LDLT in a patient with preoperative fungal liver
and splenic abscesses which was treated with amphoteri-
cin B for 3 months before liver transplant [9].
Patients with ESLD and preoperative fungal infection
may become possible liver transplant candidate by
complete elimination of fungal infectious lesions and ad-
equate antifungal treatment before liver transplantation.
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